SG11201907744QA - Replacement of cytotoxic preconditioning before cellular immunotherapy - Google Patents

Replacement of cytotoxic preconditioning before cellular immunotherapy

Info

Publication number
SG11201907744QA
SG11201907744QA SG11201907744QA SG11201907744QA SG11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA
Authority
SG
Singapore
Prior art keywords
international
pct
cytotoxic preconditioning
cellular
cytotoxic
Prior art date
Application number
SG11201907744QA
Other languages
English (en)
Inventor
Theresa Ann Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of SG11201907744QA publication Critical patent/SG11201907744QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11201907744QA 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy SG11201907744QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762480414P 2017-04-01 2017-04-01
US201862613697P 2018-01-04 2018-01-04
US201862624454P 2018-01-31 2018-01-31
PCT/US2018/025517 WO2018183927A1 (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Publications (1)

Publication Number Publication Date
SG11201907744QA true SG11201907744QA (en) 2019-09-27

Family

ID=62111173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907744QA SG11201907744QA (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Country Status (13)

Country Link
US (2) US11219628B2 (es)
EP (1) EP3490605B1 (es)
JP (2) JP6748221B2 (es)
KR (1) KR102509006B1 (es)
CN (1) CN110475571B (es)
AU (1) AU2018243753A1 (es)
BR (1) BR112019020214A2 (es)
CA (1) CA3054443A1 (es)
ES (1) ES2954311T3 (es)
IL (1) IL269209B2 (es)
MX (1) MX2019011679A (es)
SG (1) SG11201907744QA (es)
WO (1) WO2018183927A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP6748221B2 (ja) 2017-04-01 2020-08-26 エーブイエム・バイオテクノロジー・エルエルシー 細胞免疫療法前の細胞毒性プレコンディショニングの代替
CA3066361A1 (en) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
CN111556763B (zh) 2017-11-13 2023-09-01 施菲姆德控股有限责任公司 血管内流体运动装置、系统
EP3746149A4 (en) 2018-02-01 2021-10-27 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHODS OF USE AND METHODS OF MANUFACTURING
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
CA3118505A1 (en) * 2018-11-14 2020-05-22 Avm Biotechnology, Llc Stable glucocorticoid formulation
WO2020123444A1 (en) * 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
AU2020380366A1 (en) * 2019-11-06 2022-05-26 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
CN113189340A (zh) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 细胞焦亡通路在细胞治疗中的用途
WO2021168375A1 (en) * 2020-02-20 2021-08-26 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
US20230096897A1 (en) 2020-02-28 2023-03-30 Avm Biotechnology, Llc Lymphocyte Population and Methods for Producing Same
WO2021207724A2 (en) * 2020-04-10 2021-10-14 North Carolina State University Enhanced viral transduction of mammalian cells using material scaffolds
CN111443210B (zh) * 2020-04-10 2023-09-22 青海大学附属医院 泡型包虫病早期诊疗生物标志物及其应用
CN115666583A (zh) 2020-04-29 2023-01-31 Avm生物技术有限责任公司 用于治疗sars-cov-2病毒的糖皮质激素受体(gr)调节剂
KR20230018422A (ko) 2020-06-01 2023-02-07 에이브이엠 바이오테크놀로지, 엘엘씨 Icam-조절제를 이용한 치료 방법
WO2022049572A1 (en) * 2020-09-01 2022-03-10 The National Institute for Biotechnology in the Negev Ltd. Immune system restoration by cell therapy
CN113322233A (zh) * 2021-04-19 2021-08-31 格源致善(上海)生物科技有限公司 一种改进的基于新生抗原反应性t细胞的制备方法及应用
CN116063401B (zh) * 2021-08-13 2023-12-01 中国人民解放军总医院 阻断型靶向pd-l1的超高亲和力小蛋白及用途
CA3229529A1 (en) 2021-09-01 2023-03-09 Avm Biotechnology, Llc Lymphocyte population and methods for producing same
CN114031678A (zh) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 一种条斑钳蝎毒素多肽组分的制备方法及其应用
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
CN116606352B (zh) * 2023-07-14 2023-09-29 诺赛联合(北京)生物医学科技有限公司 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
DE69739344D1 (de) 1997-12-16 2009-05-14 Univ Zuerich T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
AU2003225791A1 (en) 2002-03-15 2003-09-29 Department Of Veterans Affairs, Rehabilitation R And D Service Methods and compositions for directing cells to target organs
CN103393695A (zh) 2002-05-17 2013-11-20 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
AU2005322068B2 (en) 2004-12-23 2011-09-01 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
EP1874821B1 (de) * 2005-04-26 2013-04-17 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US20100247491A1 (en) 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
WO2009142759A1 (en) * 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
EP2300599B1 (en) 2008-06-09 2017-03-01 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
KR20190017065A (ko) * 2010-08-18 2019-02-19 테레사 데이셔 림프양 조직에 줄기 세포와 조상 세포 결합을 저해하고, 그리고 림프 조직에서 배 중심을 재생하기 위한 조성물과 방법
KR20230133410A (ko) 2010-12-09 2023-09-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
EA201391059A1 (ru) 2011-01-18 2014-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции для лечения рака и способы их применения
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP2756521A4 (en) 2011-09-16 2015-04-22 Univ Pennsylvania RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
HUE054588T2 (hu) * 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
EP3250605A1 (en) * 2015-01-26 2017-12-06 Cellectis Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
IL295224A (en) * 2015-05-28 2022-10-01 Kite Pharma Inc Methods for training patients for t-cell therapy
WO2018102606A1 (en) * 2016-11-30 2018-06-07 Intrexon Corporation Steroid administration and immunotherapy
JP6748221B2 (ja) 2017-04-01 2020-08-26 エーブイエム・バイオテクノロジー・エルエルシー 細胞免疫療法前の細胞毒性プレコンディショニングの代替

Also Published As

Publication number Publication date
KR102509006B1 (ko) 2023-03-13
AU2018243753A1 (en) 2019-10-10
CN110475571A (zh) 2019-11-19
US20180296572A1 (en) 2018-10-18
EP3490605B1 (en) 2023-06-07
CN110475571B (zh) 2023-04-04
US20220160729A1 (en) 2022-05-26
MX2019011679A (es) 2019-11-01
JP6748221B2 (ja) 2020-08-26
CA3054443A1 (en) 2018-10-14
JP2019515888A (ja) 2019-06-13
US11219628B2 (en) 2022-01-11
ES2954311T3 (es) 2023-11-21
IL269209B2 (en) 2023-11-01
IL269209A (en) 2019-11-28
EP3490605A1 (en) 2019-06-05
JP2020114837A (ja) 2020-07-30
IL269209B1 (en) 2023-07-01
WO2018183927A1 (en) 2018-10-04
BR112019020214A2 (pt) 2020-04-22
KR20190130624A (ko) 2019-11-22
JP7162632B2 (ja) 2022-10-28
EP3490605C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
SG11201907744QA (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201811074RA (en) Nant cancer vaccine
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201808108XA (en) Synthesis of indazoles
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201407200TA (en) Liquid formulation
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201805001UA (en) Method of treating influenza a
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900043TA (en) Antibody formulations
SG11201900361RA (en) Methods of treating prostate cancer
SG11201810940XA (en) Methods of treating pancreatic cancer